Alfatide II

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 125677


Description: Alfatide II is ligand for making 18F-Alfatide II PET/CT for Identification of Breast Cancer: A Preliminary Clinical Study. 18F-alfatide II has been proven to have excellent clinical translational potential.

Chemical Structure

Alfatide II

Theoretical Analysis

MedKoo Cat#: 125677
Name: Alfatide II
Chemical Formula: C87H128N24O28S
Exact Mass: 1,988.91
Molecular Weight: 1,990.180
Elemental Analysis: C, 52.51; H, 6.48; N, 16.89; O, 22.51; S, 1.61

Price and Availability

Size Price Availability Quantity
10mg USD 1250 2 Weeks
50mg USD 2050 2 Weeks
100mg USD 3850 2 Weeks
Bulk inquiry

Synonym: Alfatide II; Alfatide-II; AlfatideII

IUPAC/Chemical Name: 2,2',2''-(2-(4-(3-(13-((4-((2S,5S,11S,14R)-11-(carboxymethyl)-5-(3-guanidinopropyl)-14-(4-hydroxybenzyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaazacyclopentadecan-2-yl)butyl)carbamoyl)-21-((2S,5S,11S,14R)-11-(carboxymethyl)-5-(3-guanidinopropyl)-14-(4-hydroxybenzyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaazacyclopentadecan-2-yl)-11,16-dioxo-3,6,9-trioxa-12,17-diazahenicosyl)thioureido)benzyl)-1,4,7-triazonane-1,4,7-triyl)triacetic acid


InChi Code: InChI=1S/C87H128N24O28S/c88-85(89)94-27-5-9-58-77(129)97-44-68(115)101-65(42-71(118)119)83(135)107-63(40-52-13-19-56(112)20-14-52)81(133)105-60(79(131)103-58)7-1-3-25-92-67(114)24-23-62(100-70(117)50-139-38-37-138-36-35-137-34-29-96-87(140)99-54-17-11-51(12-18-54)39-55-46-110(48-74(124)125)31-30-109(47-73(122)123)32-33-111(55)49-75(126)127)76(128)93-26-4-2-8-61-80(132)104-59(10-6-28-95-86(90)91)78(130)98-45-69(116)102-66(43-72(120)121)84(136)108-64(82(134)106-61)41-53-15-21-57(113)22-16-53/h11-22,55,58-66,112-113H,1-10,23-50H2,(H,92,114)(H,93,128)(H,97,129)(H,98,130)(H,100,117)(H,101,115)(H,102,116)(H,103,131)(H,104,132)(H,105,133)(H,106,134)(H,107,135)(H,108,136)(H,118,119)(H,120,121)(H,122,123)(H,124,125)(H,126,127)(H4,88,89,94)(H4,90,91,95)(H2,96,99,140)/t55?,58-,59-,60-,61-,62?,63+,64+,65-,66-/m0/s1


Appearance: To be determined

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 1,990.18 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Wu J, Wang S, Zhang X, Teng Z, Wang J, Yung BC, Niu G, Zhu H, Lu G, Chen X.
18F-Alfatide II PET/CT for Identification of Breast Cancer: A
Preliminary Clinical Study. J Nucl Med. 2018 Dec;59(12):1809-1816. doi:
10.2967/jnumed.118.208637. Epub 2018 Apr 26. PMID: 29700127; PMCID: PMC6910641.

2: Wu J, Tian J, Zhang Y, Ji H, Sun J, Wang X, Sun C, Wang L, Teng Z, Lu G, Zhu
H, Chen X. 18F-Alfatide II for the evaluation of axillary lymph nodes
in breast cancer patients: comparison with 18F-FDG. Eur J Nucl Med
Mol Imaging. 2022 Jul;49(8):2869-2876. doi: 10.1007/s00259-021-05333-z. Epub
2022 Feb 9. PMID: 35138445.

3: Yu C, Pan D, Mi B, Xu Y, Lang L, Niu G, Yang M, Wan W, Chen X. (18)F-Alfatide
II PET/CT in healthy human volunteers and patients with brain metastases. Eur J
Nucl Med Mol Imaging. 2015 Dec;42(13):2021-8. doi: 10.1007/s00259-015-3118-2.
Epub 2015 Jul 1. PMID: 26121930; PMCID: PMC4626365.

4: Mi B, Yu C, Pan D, Yang M, Wan W, Niu G, Chen X. Pilot Prospective Evaluation
of (18)F-Alfatide II for Detection of Skeletal Metastases. Theranostics. 2015
Jul 12;5(10):1115-21. doi: 10.7150/thno.12938. PMID: 26199649; PMCID:

5: Wu J, Zhang X, Jia Z, Zhou X, Qi R, Ji H, Sun J, Sun C, Teng Z, Lu G, Chen X.
Combined 18F-FDG and 18F-Alfatide II PET May Predict
Luminal B (HER2 Negative) Subtype and Nonluminal Subtype of Invasive Breast
Cancer. Mol Pharm. 2022 Sep 5;19(9):3405-3411. doi:
10.1021/acs.molpharmaceut.2c00547. Epub 2022 Aug 16. PMID: 35972444.